Symbols / BBLG Stock $1.24 +1.64%
BBLG (Stock) Chart
About
Asset: Stock
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.23M |
| Enterprise Value | -3.11M | Income | -3.11M | Sales | — |
| Book/sh | 3.00 | Cash/sh | 2.97 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | — | Forward P/E | -0.77 | PEG | — |
| P/S | — | P/B | 0.41 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 12.77 |
| Current Ratio | 13.85 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.69 | EPS next Y | -1.62 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-02 16:00 | ROA | -41.87% |
| ROE | -70.17% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.80M |
| Shs Float | 1.79M | Short Float | 1.69% | Short Ratio | 1.67 |
| Short Interest | — | 52W High | 6.75 | 52W Low | 1.11 |
| Beta | 0.42 | Avg Volume | 313.91K | Volume | 13.64K |
| Target Price | $22.20 | Recom | Strong_buy | Prev Close | $1.22 |
| Price | $1.24 | Change | 1.64% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$22.20
Mean price target
2. Current target
$1.24
Latest analyst target
3. DCF / Fair value
$-16.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.24
Low
$22.20
High
$22.20
Mean
$22.20
- Bone-healing treatment in development now lasts 2 years on the shelf in tests - Stock Titan ue, 23 Dec 2025 08
- Bone Biologics stock rises after extending product shelf life - Investing.com ue, 23 Dec 2025 08
- AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI ue, 03 Mar 2026 21
- Bone Biologics files $35M mixed shelf offering - MSN Fri, 20 Feb 2026 13
- BBLG Stocks on the Verge: How Will They Perform? - StocksToTrade ue, 23 Dec 2025 08
- Bone Biologics To Implement 1-for-6 Reverse Stock Split Effective June 10, 2025 - Nasdaq Fri, 06 Jun 2025 07
- Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook - Yahoo Finance hu, 04 Sep 2025 07
- BBLG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan Sat, 14 Feb 2026 02
- Bone Biologics 10-K: Operating loss $3.23M, net loss $3.11M; EPS impact noted - TradingView Mon, 02 Mar 2026 21
- Bone Biologics Announces 1-for-6 Reverse Stock Split - citybiz Fri, 06 Jun 2025 07
- Bone Biologics expects to complete enrollment in NB1 clinical trial - Investing.com hu, 04 Sep 2025 07
- symbol__ Stock Quote Price and Forecast - CNN ue, 26 Mar 2024 11
- Spine Fusion Developer Bone Biologics to Showcase at Major H.C. Wainwright Investment Conference - Stock Titan Wed, 03 Sep 2025 07
- What is the current Price Target and Forecast for Bone Biologics (BBLG) - Zacks Investment Research Mon, 26 Sep 2022 06
- Bone Biologics launches $1.06 million at-the-market offering on Nasdaq - Investing.com UK Fri, 13 Mar 2026 21
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -3.24M | -4.27M | -9.91M | -6.58M |
| TotalUnusualItems | 3.97K | 51.08K | 477.70K | 2.91M |
| TotalUnusualItemsExcludingGoodwill | 3.97K | 51.08K | 477.70K | 2.91M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -3.11M | -4.11M | -8.95M | -1.48M |
| ReconciledCostOfRevenue | 0.00 | 0.00 | ||
| EBITDA | -3.23M | -4.22M | -9.43M | -3.67M |
| EBIT | -3.23M | -4.22M | -9.43M | -3.67M |
| NetInterestIncome | 121.98K | 55.66K | 1.87K | -731.71K |
| InterestExpense | 0.00 | 805.11K | ||
| InterestIncome | 121.98K | 55.66K | 1.87K | 0.00 |
| NormalizedIncome | -3.11M | -4.16M | -9.43M | -4.40M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -3.11M | -4.11M | -8.95M | -1.48M |
| TotalExpenses | 3.23M | 4.22M | 9.43M | 3.67M |
| TotalOperatingIncomeAsReported | -3.23M | -4.22M | -9.43M | -3.67M |
| DilutedAverageShares | 252.96K | 43.86K | 7.94K | 3.15K |
| BasicAverageShares | 252.96K | 43.86K | 7.94K | 3.15K |
| DilutedEPS | -28.96 | -204.06 | -186.90 | -504.00 |
| BasicEPS | -28.96 | -204.06 | -186.90 | -504.00 |
| DilutedNIAvailtoComStockholders | -3.11M | -7.32M | -8.95M | -1.48M |
| NetIncomeCommonStockholders | -3.11M | -7.32M | -8.95M | -1.48M |
| OtherunderPreferredStockDividend | 0.00 | 3.21M | 0.00 | |
| NetIncome | -3.11M | -4.11M | -8.95M | -1.48M |
| NetIncomeIncludingNoncontrollingInterests | -3.11M | -4.11M | -8.95M | -1.48M |
| NetIncomeContinuousOperations | -3.11M | -4.11M | -8.95M | -1.48M |
| TaxProvision | 1.60K | |||
| PretaxIncome | -3.11M | -4.11M | -8.95M | -1.48M |
| OtherIncomeExpense | 3.97K | 51.08K | 477.70K | 2.91M |
| SpecialIncomeCharges | 0.00 | -414.99K | 0.00 | 297.50K |
| OtherSpecialCharges | 414.99K | -297.50K | ||
| GainOnSaleOfSecurity | 3.97K | 51.08K | 892.69K | 2.91M |
| NetNonOperatingInterestIncomeExpense | 121.98K | 55.66K | 1.87K | -731.71K |
| TotalOtherFinanceCost | 731.71K | |||
| InterestExpenseNonOperating | 0.00 | 805.11K | ||
| InterestIncomeNonOperating | 121.98K | 55.66K | 1.87K | 0.00 |
| OperatingIncome | -3.23M | -4.22M | -9.43M | -3.67M |
| OperatingExpense | 3.23M | 4.22M | 9.43M | 3.67M |
| ResearchAndDevelopment | 1.06M | 2.13M | 6.91M | 1.58M |
| SellingGeneralAndAdministration | 2.17M | 2.09M | 2.52M | 2.09M |
| GeneralAndAdministrativeExpense | 2.17M | 2.09M | 2.52M | 2.09M |
| OtherGandA | 2.17M | 2.09M | 2.52M | 2.09M |
| GrossProfit | 0.00 | 0.00 | ||
| CostOfRevenue | 0.00 | 0.00 | ||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 1.80M | 492.33K | 89.04K | 10.63K |
| ShareIssued | 1.80M | 492.33K | 89.04K | 10.63K |
| TangibleBookValue | 5.38M | 3.48M | 2.91M | 5.95M |
| InvestedCapital | 5.38M | 3.48M | 2.91M | 5.95M |
| WorkingCapital | 5.38M | 3.48M | 2.91M | 5.95M |
| NetTangibleAssets | 5.38M | 3.48M | 2.91M | 5.95M |
| CommonStockEquity | 5.38M | 3.48M | 2.91M | 5.95M |
| TotalCapitalization | 5.38M | 3.48M | 2.91M | 5.95M |
| TotalEquityGrossMinorityInterest | 5.38M | 3.48M | 2.91M | 5.95M |
| StockholdersEquity | 5.38M | 3.48M | 2.91M | 5.95M |
| RetainedEarnings | -88.13M | -85.02M | -80.91M | -71.96M |
| AdditionalPaidInCapital | 93.51M | 88.50M | 83.81M | 77.91M |
| CapitalStock | 1.79K | 492.00 | 534.00 | 64.00 |
| CommonStock | 1.79K | 492.00 | 534.00 | 64.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 418.59K | 377.71K | 831.40K | 2.55M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 418.59K | 377.71K | 831.40K | 2.55M |
| OtherCurrentLiabilities | 703.00 | 4.67K | 55.75K | 1.66M |
| CurrentDeferredLiabilities | 0.00 | 0.00 | 783.67K | 0.00 |
| CurrentDeferredRevenue | 0.00 | 0.00 | 783.67K | |
| LineOfCredit | 0.00 | |||
| CurrentNotesPayable | 0.00 | |||
| PayablesAndAccruedExpenses | 417.88K | 373.04K | 775.65K | 104.79K |
| CurrentAccruedExpenses | 0.00 | 414.99K | 0.00 | |
| InterestPayable | 0.00 | |||
| Payables | 417.88K | 373.04K | 360.66K | 104.79K |
| AccountsPayable | 417.88K | 373.04K | 360.66K | 104.79K |
| TotalAssets | 5.80M | 3.86M | 3.74M | 8.50M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 5.80M | 3.86M | 3.74M | 8.50M |
| PrepaidAssets | 451.92K | 536.24K | 711.19K | 956.92K |
| Receivables | 9.89K | 0.00 | 328.84K | 579.91K |
| OtherReceivables | 328.84K | 579.91K | ||
| AccruedInterestReceivable | 9.89K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 5.33M | 3.33M | 3.03M | 7.54M |
| CashAndCashEquivalents | 5.33M | 3.33M | 3.03M | 7.54M |
| CashFinancial | 5.33M | 3.33M | 3.03M | 7.54M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -2.69M | -4.12M | -9.56M | -3.57M |
| RepaymentOfDebt | 0.00 | -10.61K | ||
| IssuanceOfDebt | 0.00 | 1.06M | ||
| IssuanceOfCapitalStock | 4.70M | 2.62M | 5.04M | 4.43M |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 12.06K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 5.33M | 3.33M | 3.03M | 7.54M |
| BeginningCashPosition | 3.33M | 3.03M | 7.54M | 6.68M |
| ChangesInCash | 2.01M | 298.56K | -4.51M | 862.95K |
| FinancingCashFlow | 4.70M | 4.42M | 5.04M | 4.43M |
| CashFlowFromContinuingFinancingActivities | 4.70M | 4.42M | 5.04M | 4.43M |
| ProceedsFromStockOptionExercised | 0.00 | 1.81M | 0.00 | |
| NetCommonStockIssuance | 4.70M | 2.62M | 5.04M | 4.43M |
| CommonStockIssuance | 4.70M | 2.62M | 5.04M | 4.43M |
| NetIssuancePaymentsOfDebt | 0.00 | 1.05M | ||
| NetShortTermDebtIssuance | 0.00 | 1.05M | ||
| ShortTermDebtPayments | 0.00 | -10.61K | ||
| ShortTermDebtIssuance | 0.00 | 1.06M | ||
| OperatingCashFlow | -2.69M | -4.12M | -9.56M | -3.57M |
| CashFlowFromContinuingOperatingActivities | -2.69M | -4.12M | -9.56M | -3.57M |
| ChangeInWorkingCapital | 165.45K | -150.25K | 132.92K | -168.37K |
| ChangeInOtherWorkingCapital | -783.67K | 783.67K | 45.00K | |
| ChangeInPayablesAndAccruedExpense | 91.03K | -325.21K | 670.87K | 4.88K |
| ChangeInAccruedExpense | 0.00 | -414.99K | 414.99K | 0.00 |
| ChangeInPayable | 91.03K | 89.78K | 255.88K | 4.88K |
| ChangeInAccountPayable | 91.03K | 89.78K | 255.88K | 4.88K |
| ChangeInPrepaidAssets | 84.32K | 174.96K | 245.73K | -956.92K |
| ChangeInReceivables | -9.89K | |||
| OtherNonCashItems | 731.71K | 495.55K | ||
| StockBasedCompensation | 256.36K | 188.82K | 152.60K | 266.63K |
| OperatingGainsLosses | -3.97K | -51.08K | -892.69K | -2.91M |
| GainLossOnInvestmentSecurities | -3.97K | -51.08K | -892.69K | -2.91M |
| NetIncomeFromContinuingOperations | -3.11M | -4.11M | -8.95M | -1.48M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BBLG
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|